Abstract #2953

Disease-modifying therapies and the longitudinal improvement of the thalamocortical white matter network in people with multiple sclerosis

Oun Al-iedani^1,2, Abdulaziz Alshehri^2,3,4, Nikitas Koussis², Ibrahim Khormi^2,4,5, Rodney Lea², Saadallah Ramadan^2,4, and Jeannette Lechner-Scott^2,6,7

¹School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia, ²Hunter Medical Research Institute, New Lambton Heights, Australia, ³King Fahd University Hospital, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, ⁴School of Health Sciences, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia, ⁵College of Applied Medical Sciences, University of Jeddah, Jeddah, Saudi Arabia, ⁶Department of Neurology, John Hunter Hospital, New Lambton Heights, Australia, ⁷School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, Australia

Synopsis

Keywords: Multiple Sclerosis, Multiple Sclerosis

Motivation: Relapse-remitting multiple sclerosis (RRMS) induces widespread changes in white matter (WM), affecting crucial functions. This novel longitudinal study investigates these alterations using advanced MRI, potentiating improved diagnosis and treatment.

Goal(s): To investigate differences in WM microstructure on a network level between RRMS and healthy controls (HCs) over two years.

Approach: Advanced MRI (diffusion-weighted imaging and tractography) was used in a network-based analysis of WM tracts, comparing RRMS to HCs.

Results: Our findings reveal widespread WM disparities in RRMS. We identified network differences between RRMS and HCs, offering valuable insights into RRMS pathophysiology and potential remyelination during disease-modifying treatments.

Impact: This novel study reveals widespread white matter differences in relapse-remitting multiple sclerosis (RRMS) patients, providing crucial insights into RRMS pathophysiology. It highlights potential remyelination during treatment, offering promise for improved diagnosis and therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.